Koch, M. ; de Jong, J.S.* ; Glatz, J. ; Symvoulidis, P. ; Lamberts, L.E.* ; Adams, A.L.L.* ; Kranendonk, M.E.G.* ; van Scheltinga, A.T.* ; Aichler, M. ; Jansen, L.* ; de Vries, J.* ; Lub-de Hooge, M.* ; Schröder, C.P.* ; Jorritsma-Smit, A.* ; Linssen, M.D.* ; de Boer, E.* ; van der Vegt, B.* ; Nagengast, W.B.* ; Elias, S.G.* ; Oliveira, S.* ; Witkamp, A.J.* ; Mali, W.P.Th.M.* ; van der Wall, E.* ; Garcia-Allende, P. ; van Diest, P.J.* ; de Vries, E.G.* ; Walch, A.K. ; van Dam, G.M.* ; Ntziachristos, V.
Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold.
Proc. SPIE 10411:104110F (2017)
In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Imaging systems, Medical and biological imaging, Clinical applications
Keywords plus
Language
english
Publication Year
2017
Prepublished in Year
HGF-reported in Year
2017
ISSN (print) / ISBN
0277-786X
e-ISSN
1996-756X
ISBN
Book Volume Title
Conference Title
European Conferences on Biomedical Optics
Conference Date
25-29 June 2017
Conference Location
Munich, Germany
Proceedings Title
Quellenangaben
Volume: 10411,
Issue: ,
Pages: ,
Article Number: 104110F
Supplement: ,
Series
Publisher
SPIE
Publishing Place
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30205 - Bioengineering and Digital Health
Research field(s)
Enabling and Novel Technologies
PSP Element(s)
G-505500-001
G-500390-001
Grants
Copyright
Erfassungsdatum
2017-09-06